Topics & News
-
open_in_newABE & PARTNERS represented Regeneron Pharmaceuticals against Samsung Bioepis in an Unfair Competition PI Case and received a dismissal decision.
-
German Law & Patent Firm has visited ABE & PARTNERS.
-
UK Law Firm has visited ABE & PARTNERS.
-
open_in_newTakanori ABE gave a speech at AIPPI Pharma Webinar "What Discovery Mechanisms Exist in China, Japan, Korea, and India to Aid in the Preparation of a Preliminary Injunction (PI) Request or General Evidence Gathering?".
-
open_in_newABE & PARTNERS represented Bayer Healthcare against Samsung Bioepis in an Unfair Competition PI Case and received a dismissal decision.
-
US Law Firm has visited ABE & PARTNERS.
-
ABE & PARTNERS represented U.S. Pharmaceutical Company against X in Patent Opposition and received a decision to maintain the patent.
-
Takanori ABE gave a speech regarding Japanese pharmaceutical patent litigation at the client company (a pharmaceutical company, listed on the Prime Market of Tokyo Stock Exchange).
-
Takanori ABE gave a lecture entitled "How was Japanese patent litigation reformed" at Japan-China IP Conference organized by JAPIT.
-
open_in_newTakanori ABE's article titled "Patent royalty claim dismissed due to a demurrer, admitting the reach of an arbitration agreement - Defendants' measures and plaintiffs? risk reduction -" had been published on Japan Commercial Arbitration Journal Vol. 5 [2024].
-
Chinese Law Firm has visted ABE & PARTNERS.
-
ABE & PARTNERS represented Japanese Pharmaceutical Company against Indian Pharmaceutical Company in the Trial for Patent Invalidation for vaccine patent case and received invalidity decision.
-
Takanori ABE's comment appeared in an article titled "Avoiding disputes between university and industry, patent agreements are critical" in Yomiuri Newspaper.
-
Takanori ABE has been selected as IP Star 2024 by Managing Intellectual Property.
-
NEWTakanori ABE was selected as SILVER by IAM Patent 1000 2024 in the category of Litigation.
-
Takanori ABE gave a lecture entitled "Medical Standard of Care" at Faculty of Medicine, Osaka University.
-
open_in_newABE & PARTNERS has been ranked Tier2 in Japan Domestic, Patents by Asian Legal Business' ALB 2024 IP Ranking.
-
open_in_newTakanori ABE's interviewed article titled "Five minutes with…Takanori Abe, Abe & Partners" had been published on Managing Intellectual Property.
-
Singaporean Law Firm has visited ABE & PARTNERS.
-
Takanori ABE published the article titled "Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism".
-
open_in_newTakanori ABE's article titled "Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism" had been published on LSIPR.
-
German Law & Patent Firm has visited ABE & PARTNERS.
-
open_in_newTakanori ABE has been selected as Top 50 IP Experts of Japan 2024 by Asia IP.
-
open_in_newTakanori ABE gave a speech entitled "Amgen v. Sanofi/Regeneron in Japan" at the session "Amgen vs Sanofi/Regeneron” at Pharma & Biotech Patent Litigation Summit, Europe.
-
Takanori ABE published the article titled "Preliminary injunctions in pharmaceutical patent cases in Japan".
-
open_in_newTakanori ABE's article titled "Preliminary injunctions in pharmaceutical patent cases in Japan" had been published on LSIPR.
-
open_in_newTakanori ABE gave a speech entitled "Japan, Pharma and Biotech Patent Litigation Case Law Review" at Pharma & Biotech Patent Litigation Summit, Europe.
- 1
2024